Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-1-naphthyl-2-acetamido-ethane boronic acid is an experimental small molecule compound containing a naphthalene moiety and a boronic acid functional group. It has been studied primarily as a transition-state analog inhibitor of serine proteases, such as chymotrypsin and subtilisin, by forming covalent tetrahedral adducts with the catalytic serine residue in the enzyme active site. This mechanism mimics the transition state of peptide bond hydrolysis, making it useful for probing enzyme stereoselectivity and inhibition mechanisms in biochemical research[8]. The compound is not approved for clinical use or marketed under any brand name[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-1-naphthyl-2-acetamido-ethane boronic acid.